Brief: Biomerieux Gets U.S. FDA Clearance For New Version Of BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
Feb 11 (Reuters) - Biomerieux SA BIOX.PA :
* ANNOUNCED ON TUESDAY IT RECEIVED U.S. FDA CLEARANCE FOR
NEW
VERSION OF MOLECULAR TEST TARGETING CAUSES OF GASTROENTERITIS,
BIOFIRE® FILMARRAY® GASTROINTESTINAL (GI) PANEL MID
* BIOFIRE® GASTROINTESTINAL (GI) PANEL MID TO BE
COMMERCIALLY
AVAILABLE IN U.S. AT END OF H1 2025
Source text: https://tinyurl.com/4vv6xxfd
Further company coverage: BIOX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biomerieux SA
See all newsBrief: Biomerieux Receives US FDA 510(K) Clearance And Ivdr CE Marking For Vitek Pro
Brief: bioMerieux Receives FDA Clearance For Latest Versions Of Biofire® Filmarray
Europe Research Roundup: Asos, Erste Group, SCHOTT pharma
Europe Research Roundup: Acceler8 Ventures, Hermes, Soitec
BioMerieux shares rise after Q3 sales beat